Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

LabCorp In Definitive Agreement to Acquire US Pathology Labs

By Pharmaceutical Processing | December 15, 2004

BURLINGTON, NC (December 15, 2004) – Laboratory Corp. of America Holdings (LabCorp) and US Pathology Labs, Inc. (US Labs), a provider of anatomic pathology and oncology testing services with a focus on the outpatient market, have entered into a definitive agreement under which LabCorp will acquire all of the outstanding shares of US Labs for approximately $155 million in cash.

The transaction, which is subject to regulatory and US Labs shareholder approval, is expected to close in the first quarter of 2005.

“The proposed acquisition of US Labs is a key part of LabCorp’s efforts to continue to be a leading provider of anatomical pathology services, an important part of our cancer strategy,” said Tom MacMahon, LabCorp’s chairman and chief executive officer. “In addition to acquiring a leading independent pathology laboratory, this acquisition provides LabCorp the opportunity to perform other esoteric and genomic tests in US Labs’ California facility, a key strategic need to our organization.”

The US Labs management team has agreed “to continue on in their current responsibilities, as part of LabCorp,” MacMahon said.”

US Labs, based in Irvine, CA, provides diagnostic, prognostic, and predictive cancer testing services to hospitals, physician offices and surgery centers.

LabCorp labels itself as a pioneer in commercializing new diagnostic technologies and the first in its industry to embrace genomic testing. With annual revenues of $2.9 billion in 2003 and approximately 23,000 employees, LabCorp offers more than 4,400 clinical assays ranging from blood analyses to HIV and genomic testing.

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE